Lung Cancer in Patients with Severe Idiopathic Pulmonary Fibrosis: Critical Aspects

• Published in: In vivo (Athens) 2017-07, Vol.31 (4), p.773-777
• Main Authors: Bargagli, Elena, Bonti, Viola, Ferrari, Katia, Rosi, Elisabetta, Bindi, Alessandra, Bartolucci, Maurizio, Chiara, Moroni, Voltolini, Luca
• Format: Article
• Language: English
• Subjects: Aged; Humans; Idiopathic Pulmonary Fibrosis - complications; Idiopathic Pulmonary Fibrosis - drug therapy; Idiopathic Pulmonary Fibrosis - pathology; Indoles - administration & dosage; Indoles - adverse effects; Lung Neoplasms - complications; Lung Neoplasms - drug therapy; Lung Neoplasms - pathology; Male; Prognosis
• ISSN: 1791-7549; 0258-851X; 1791-7549
• DOI: 10.21873/invivo.11130

Idiopathic pulmonary fibrosis (IPF) is a rare interstitial lung disease limited to the lung with an undefined etiopathogenesis and a very short life expectancy (less than 5 years). IPF susceptibility has been associated with several genetic and environmental risk factors and the prognosis is conditioned by comorbidities such as gastro-esophageal reflux, depression, venous thromboembolism, pulmonary hypertension and lung cancer. At 5 years follow-up, 15% of IPF patients develop lung cancer, which can significantly reduce their survival. Because diagnostic or therapeutic procedures such as surgical, radiation or pharmacological treatments may induce acute exacerbations and increase mortality, the management of lung cancer in IPF patients is a very difficult task. This study discusses advantages and disadvantages of lung cancer treatments in patients with severe IPF, highlighting several controversial aspects on this topic, including potential nintedanib treatment.